No Data
Solid Earnings May Not Tell The Whole Story For Henan Taloph Pharmaceutical StockLtd (SHSE:600222)
Tailong Pharmaceutical Report for the Third Quarter of 2024
Henan Taloph Pharmaceutical Stock (600222.SH): The net income for the first three quarters was 28.8959 million yuan, a year-on-year increase of 270.72%.
On October 24, Gelonhui reported that Henan Taloph Pharmaceutical Stock (600222.SH) released its third quarter report for 2024, with the company's revenue for the first three quarters of the year at 1.341 billion yuan, a 7.08% year-on-year decrease; net income attributable to shareholders of the listed company was 28.8959 million yuan, a 270.72% year-on-year increase; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 19.4868 million yuan, a 181.61% year-on-year increase; and the basic earnings per share was 0.0519 yuan.
henan taloph pharmaceutical stock (600222.SH): Currently, products such as Huoxiang Zhengqi Formula, Wuzi Yanzong Oral Liquid, and Shengmai Yin have all been successfully launched for production.
On October 8th, Henan Taloph Pharmaceutical Stock (600222.SH) stated in a recent performance briefing that the company adheres to the operation philosophy of being an expert in traditional chinese medicine oral liquids, market-driven, and in recent years has continuously increased the production of chinese patent medicine products through product introduction, research on classic formulas, and development of drugs with the same name and formula, promoting the diversified development of products and constructing a scientific product portfolio. Currently, products introduced such as the Huoxiang Zhengqi mixture, Wuzi Yanzong oral liquid, Shengmai Yin, have all been successfully launched for production.
There's No Escaping Henan Taloph Pharmaceutical Stock Co.,Ltd's (SHSE:600222) Muted Revenues
Henan Taloph Pharmaceutical Stock (600222.SH): The company did not implement share repurchase in August.
As of August 2024, Henan Taloph Pharmaceutical Stock (600222.SH) announced that the company did not implement any share repurchases. As of August 31, 2024, the company has repurchased a total of 4,693,600 shares, accounting for 0.82% of the total share capital of the company. The highest price of the repurchase transaction was 4.97 yuan/share, and the lowest price was 3.82 yuan/share. The total amount paid was 21,274,189.00 yuan (excluding transaction costs). The repurchase of the shares mentioned above complies with the relevant laws and regulations and the requirements of the company's share repurchase program.
Why Investors Shouldn't Be Surprised By Henan Taloph Pharmaceutical Stock Co.,Ltd's (SHSE:600222) 30% Share Price PlungeNo Data
No Data
